InterCure to Announce Q4 & Year-End 2021 Financial Results on April 4, 2022
InterCure (NASDAQ: INCR) will release its fourth quarter fiscal 2021 financial results on April 4, 2022, before market open. The company, recognized as Israel's largest licensed cannabis producer through its subsidiary Canndoc, is the fastest-growing cannabis firm outside North America. InterCure will host a live conference call and webcast at 8:30 am ET the same day to discuss these results, with details available via their website. This announcement highlights InterCure's ongoing growth and leadership in the cannabis market.
- InterCure is the fastest growing cannabis company outside North America.
- Canndoc is Israel's largest licensed cannabis producer.
- The company offers GMP certified, pharmaceutical-grade medical cannabis products.
- None.
Will release financial results for the fourth quarter of 2021 before market open on Monday, April 4, 2022
Webcast scheduled for same day at 8:30am ET
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that the Company will release financial results for its fourth quarter fiscal 2021 ended December 31, 2021 before financial markets open on April 4, 2022.
InterCure executives will host a live conference call and audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below.
To access the conference call, United States participants please dial (844) 310-5056, or for international callers, 1-706-679-4749. Conference ID: 5661207.
Participants can access the live webcast through the following link:
https://bit.ly/37N92wN
A live webcast of the conference call can be accessed on the ‘Events and Presentations’ section of the InterCure website at http://www.intercure.co.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co
FAQ
When will InterCure announce its fourth quarter financial results?
What time is the conference call for InterCure's financial results?
What is InterCure's stock symbol?
How can I access the webcast of InterCure's financial results?
